The Liver Meeting is the premier event in the field of hepatology and will take place in Boston, Massachusetts, USA, from November 10th to 14th. The comprehensive program includes scientific workshops, plenary speakers, a basic science symposium, AASLD/ASGE endoscopy courses, a hepatology skills workshop, AASLD/ILTS transplant courses, network events, digital tools, poster sessions, and exhibits featuring vendors showcasing industry-related products and services. The Metware Biotechnology team is eager to connect with attendees, so please feel free to visit our booth #D2799 from November 10th to 14th or schedule a meeting with us during the same period.
The Liver Meeting is renowned for its exceptional educational content and the participation of outstanding presenters. To grasp the scope of this conference, consider the extensive schedule which includes 190 sessions and over 500 speakers. This conference provides a perfect opportunity to stay updated on the latest research advancements and clinical techniques in the field of liver disease.
Metware Biotechnology offers Targeted Metabolomics Services for bile acids, which are synthesized in the liver and play a critical role in regulating liver disease by maintaining cholesterol balance and promoting lipid digestion and absorption. The Metware Database (MWDB) offers absolute quantification of 65 bile acids, as outlined in the table below.
Bile Acid Panel
Cholic Acid 3 Sulfate Sodium Salt(CA-3S)
Glycochenodeoxycholic Acid 3 Sulfate Disodium Salt(GCDCA-3S)
As an illustrative example, a recent publication in Hepatology titled 'Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling' described the molecular mechanisms of bile acid-induced hepatic inflammation. This research aimed to investigate the role of hepatic RUNX1 and its underlying mechanisms in cholestasis. The hepatic expression of RUNX1 was examined in cholestatic patients and mouse models, while bile acid composition in the serum of BDL mice was analyzed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Mechanistic studies indicated that elevated bile acids stimulated RUNX1 expression by activating the RUNX1-P2 promoter through the JAK/STAT3 signaling pathway. Modulating hepatic RUNX1 activity could represent a novel therapeutic target for cholestasis.
If you work with Liver research and interested in running metabolomics study with clinical samples, we offer:
Have some questions? – We are here to help!